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Background: Advanced cancer patients experience considerable symptoms, problems, and needs. Early referral of
these patients to specialised palliative care (SPC) could improve their symptoms and problems.
The Danish Palliative Care Trial (DanPaCT) investigates whether patients with metastatic cancer, who report
palliative needs in a screening, will benefit from being referred to ‘early SPC’.
Methods/Design: DanPaCT is a clinical, multicentre, parallel-group superiority trial with balanced randomisation
(1:1). The planned sample size is 300 patients. Patients are randomised to specialised palliative care (SPC) plus
standard treatment versus standard treatment. Consecutive patients from oncology departments are screened for
palliative needs with a questionnaire if they: a) have metastatic cancer; b) are 18 years or above; and c) have no
prior contact with SPC. Patients with palliative needs (i.e. symptoms/problems exceeding a certain threshold)
according to the questionnaire are eligible. The primary outcome is the change in the patients’ primary need (the
most severe symptom/problem measured with the European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30)). Secondary outcomes are other symptoms/problems (EORTC QLQ-
C30), satisfaction with health care (FAMCARE P-16), anxiety and depression (the Hospital Anxiety and Depression
scale), survival, and health care costs.
Discussion: Only few trials have investigated the effects of SPC. To our knowledge DanPaCT is the first trial to
investigate screening based ‘early SPC’ for patients with a broad spectrum of cancer diagnosis.
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The aim of palliative care is to relieve suffering and im-
prove quality of life in patients with a life-threatening dis-
ease [1]. Palliative care can be divided into basic palliative
care provided by general practitioners, home-care services,
and hospitals, and specialised palliative care (SPC) which
is offered by palliative care teams, departments of pallia-
tive medicine, and hospices [2].
In 2011, 38% of patients dying from cancer in Denmark
had been in contact with SPC [2]. Their median survival
from first contact with SPC was six weeks [2]. Our recent,
nation-wide study showed that large proportions of ad-
vanced cancer patients not in contact with SPC had
symptoms and problems such as pain, fatigue, and de-
pression [3,4]. One possible solution to the inadequate
management of symptoms could be the referral of these
patients to SPC at an earlier time in their disease trajec-
tory (‘early SPC’).
A recent randomised trial investigated ‘early SPC’ plus
standard treatment versus standard treatment alone
[5-7]. It showed that patients newly diagnosed with
metastatic lung cancer who were randomised to SPC
plus standard treatment obtained better quality of life,
less depression, and longer survival than patients receiv-
ing standard treatment. Thus, the trial provided prelim-
inary evidence that ‘early SPC’ seem beneficial in lung
cancer. However, this was a single-centre U.S.A. trial
assessing a small and selected group of patients. We
wanted to assess the effects of ‘early SPC’ in a Danish
setting and in a population with various cancer diagno-
ses. Furthermore, not all patients with metastatic cancer
need SPC and therefore including patients with noTable 1 Description of the sixspecialised palliative care centre
(2013 data)
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consultationpalliative needs may ‘dilute’ possible positive effects of
‘early SPC’. Accordingly, we therefore want to investigate
whether patients with metastatic cancer who report pal-
liative needs (symptoms and problems) in a screening
will benefit from being referred to SPC.
The aim of the present paper is to describe the Danish
Palliative Care Trial (DanPaCT) protocol.
Methods and design
Trial design
The trial is a clinical, multicentre, parallel-group super-
iority trial with balanced randomisation (1:1) conducted
at six Danish SPC centres. The protocol has been ap-
proved by the local regional ethics committee (the Ethics
Committee for the Capital Region, Denmark; journal
number H-3-2010-144) and registered at www.clinical-
trials.gov (NCT01348048).
Setting
Patients from departments of oncology are randomised
to SPC plus standard care versus standard care. Patients
are recruited at the following hospitals: Copenhagen
University Hospital (Rigshospitalet), Aarhus University
Hospital, Odense University Hospital, Herning Hospital,
and Vejle Hospital. Information about the six SPC centres
can be seen in Table 1.
Patient inclusion and exclusion criteria
Patients in contact with the oncology departments who
have cancer stage four according to the ‘TNM’ (TNM
stands for Tumor, Node, Metastases) classification [8] or
cancer in the central nervous system grade three or four,s performing the intervention in the DanPaCT trial
on Number of patients
treated peryear
Year of
establishment
(nursing homes included), 12
ds, out-patients’ clinic,
in other hospital departments.
About 400 1997
(nursing homes included), out-
nic, consultations in other
partments.
About 100 2012
(nursing homes included), three
ds, out-patients’ clinic,
s in other hospital departments.
About 380 1999
(nursing homes included), out-
nic, consultations in other
partments.
About 300 2004
(nursing homes included), out-
nic, consultations in other
partments.
About 250 2005
(nursing homes included), three
ds, out-patients’ clinic,
s in other hospital departments.
About 230 2002
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pating SPC centres, and who have not had contact with
an SPC during the previous year receive a screening
questionnaire. If, according to their answers in the ques-
tionnaire, they have a palliative need and four additional
symptoms (see definition below) they are informed
about the trial and invited to participate. Patients who
provide informed consent are randomised. Patients are
excluded from the trial if they cannot understand Danish
well enough to fill in a questionnaire or are considered
incapable of complying with the trial protocol.
Screening: assessment of palliative needs and additional
symptoms
Patients are screened with the European Organisation
for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) [9].
The EORTC QLQ-C30 [9] assesses health-related qual-
ity of life and consists of nine multi-item scales measuring:
physical function, role function, emotional function, cog-
nitive function, social functioning, global health status/
quality of life, fatigue, nausea and vomiting, and pain, and
six single-item scales: dyspnoea, insomnia, lack of appetite,
constipation, diarrhoea and financial difficulties.
Patients are defined as having a palliative need and four
additional symptoms (and are thus eligible for the trial)
if they:
 Score at least 50% of the score corresponding to
maximal symptom burden or maximally reduced
functioning on at least one of the following scales inTim
Screening We
Randomisation
We
Specialised 
palliative care 
plus standard
care
(intervention 
group)
Standard care
(control group)
We
We
3 m
3 m
Figure 1 Study measures and time points.EORTC QLQ-C30: physical function, role function,
emotional function, nausea and vomiting, pain,
dyspnoea, or lack of appetite; AND
 Have four additional symptoms (defined as EORTC
QLQ-C30 scale score of at least 33% of the score
corresponding to maximal symptom burden or
maximally reduced functioning) out of the 14
EORTC QLQ-C30 scales (global health status/
quality of life excluded).
Randomisation
Central randomisation via telephone is carried out by the
Copenhagen Trial Unit (CTU), which is independent of
the trial administration office. The allocation sequence is
computer-generated 1:1 with varying block size and is kept
unknown for all investigators. Randomisation is stratified
by the variable ’primary need’ (see description in the sec-
tion ‘Outcomes’).
Assessments and questionnaires
All randomised patients are assessed with a questionnaire
(see Figure 1): a) at baseline (the screening); b) after a 3-
week follow-up period; and c) after an 8-week follow-up
period.
The questionnaires include EORTC QLQ-C30 (de-
scribed in the section on ‘screening’), the FAMCARE-
p16 questionnaire [10] and the Hospital Anxiety and
Depression Scale (HAD scale) [11]. FAMCARE-p16 as-
sesses advanced cancer patients’ satisfaction with the
health care system. The questionnaire includes several
items that address key areas of palliative care. It uses 5-e Description Type of data
ek 0 Baseline Questionnaire
ek 1
ek 4 3-week follow-up Questionnaire
ek 9 8-week follow-up Questionnaire
Description of
treatments and contacts
Serious adverse events
Medical records,
patient registers
onths Survival
Health care service 
use
Medical records,
patient registers
onths Earliest end of trial. Possible follow-up 5 
years
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3=‘undecided’, 4=‘dissatisfied’ and 5=‘very dissatisfied’.
The patients are asked to rate the care they received
within the previous month. In addition four items meas-
uring satisfaction were developed for this particular
trial.
The HAD [11] scale assesses anxiety and depression
and was developed for people with a somatic disease.
The questionnaire has been used in many studies of ad-
vanced cancer patients, and its validity and reliability has
been tested on several occasions with a generally positive
conclusion [12].
Finally, we included six additional newly developed
items to measure pain, three items measuring appetite
loss, and three items about dyspnoea. These items were
selected from the item banks of the EORTC Compu-
terised Adaptive Testing Project [13,14] and will be used
in sensitivity analysis and subsequent methodological
analyses only.
Three months after end of the intervention informa-
tion about death, use of health services and treatments
are retrieved from registers by investigators who are
blinded and not aware of treatment allocation.
Clinical data is extracted from the medical records re-
garding primary tumour, sex, age, stage of cancer accord-
ing to the TNM system, time of primary diagnosis, and
treatment status.
To describe the interventions given and the ‘palliative
activity’ in both groups all treatments and contacts with
the health care system are registered. This is done by
reviewing the medical records from the time of random-
isation until the 8-week follow-up.Outcomes
The primary outcome is estimated as the difference be-
tween the intervention and the control group in the
change from baseline to the weighted mean of the 3-
and 8-week follow-up measured as area under the curve
(AUC) for the EORTC QLQ-C30 scale score that con-
stitutes the primary need. The primary need is defined
as the palliative need having the highest intensity at
baseline according to the EORTC QLQ-C30. Seven dif-
ferent palliative needs (listed in the section on screen-
ing) are considered when defining the primary need.
Secondary outcomes, estimated in the same way, are a)
the remaining symptoms and problems measured by the
EORTC QLQ-C30 (14 scales), b) anxiety and depression
measured by the HAD Scale c) the patients’ evaluation
of treatment and care provided by the health care sys-
tem measured by the FAMCARE-p16, d) survival, and
e) economical consequences per week from the start of
the trial to minimum three months after the end of the
intervention.Sample size estimation
We know from previous studies (unpublished data) that
the standard deviation (SD) for a difference between re-
peated measurements (three weeks apart) in the EORTC
QLQ-C30 is 15 to 22 points. Therefore, we assume that
the primary outcome has an SD of 20 points in the
present trial. We wish to be able to detect a difference of
7.5 points (a difference between 5 and 10 is normally
judged clinically significant [15]). With a risk of type I
error of 0.05 and type II error of 0.10 we need 150
patients in each intervention group, i.e., a total of 300
patients, and 50 from each centre.
Plan of analysis
Analyses will be made using SAS statistical software
version 9 [16]. The primary analysis will be based on the
intention-to-treat principle. If there are more than 5%
missing answers we will use multiple imputations with
the following variables in our model: age, sex, diagnosis,
cancer stage, and The World Health Organisations
(WHO) performance score.
Analyses will be made as multiple regressions. The pri-
mary analysis of all outcomes will be adjusted for the
stratification variable, the patient’s ‘primary need’. Sensitiv-
ity analyses will further be adjusted for WHO performance
status, and ‘centre’. If there is an imbalance in the two
treatments groups we shall further consider adjusting for
gender, age, cancer stage, diagnosis, co-morbidity, treat-
ment status and education which may have a prognostic
value [17,18].
Blinding
Allocation status cannot be blinded for the participants
and trial personnel. However, concealment of allocation
is carefully maintained during retrieval of outcome infor-
mation from national registers. Further, all statistical
analyses will be carried out blinded to intervention with
the two groups coded as, e.g., A and B. Two conclusions
will be drawn, one assuming A is the experimental
group and B is the control group, and one assuming the
opposite. After this, the blind will be broken.
Ethics
The justification for carrying out the trial is the sparse
evidence concerning the beneficial and harmful effects
of ‘early SPC’. In addition, patients randomised to stand-
ard treatment in this trial receive the same treatment as
they would have had it not been for this trial. Some of
these patients may seek referral to SPC and of course, this
will be registered but not prevented.
Discussion
Few randomised clinical trials have investigated the effect
of SPC and thus, the evidence regarding SPC is sparse
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including patients with advanced cancers from mul-
tiple organs. To our knowledge it is the first trial to in-
vestigate ‘early SPC’ for patients with a broad spectrum
of cancer diagnosis, and the first trial to investigate
screening-based referral to SPC. In addition it is the
first to provide detailed information about the specific
interventions given by the SPC centres; a knowledge
that has been requested [30].
In DanPaCT, the primary outcome is tailored to the pa-
tient by being the patient’s most pronounced symptom/
problem (‘primary need’). For some patients, the primary
outcome is pain, for others it is appetite loss. The strength
of this approach is that the primary outcome is relevant
for all patients, and that it takes into account the multidi-
mensionality of palliative care without summing up the
different symptoms/problems, which may lead to dilution
of the measurement of effect.
The treatment allocation cannot be blinded for partici-
pants and staff, which is of course a limitation [31,32].
This lack of blinding of the treatment after allocation may
have several consequences. It is possible that patients in
the SPC group will receive less attention from the oncol-
ogy departments. To determine whether this is the case,
the two groups’ number of contacts with the oncology de-
partments will be assessed and compared. Although we
consider it unlikely, it is also possible that patients in the
SPC group will receive a better SPC treatment than pa-
tients receiving usual care, and it is possible that patients
in the SPC group will underreport their symptoms at
follow-up. However, the patients are not informed about
the primary outcome of the trial. Further, assessment of
survival and health economics will be based on registry
data and hence, blinded to intervention. In addition, the
randomisation will be performed centrally and allocation
carefully concealed to the project nurses in order to avoid
selection bias, and data-analysts will be blinded to inter-
vention [31,32].
The trial does not include all relevant palliative needs
(e.g., existential and spiritual needs). In addition, patients
with metastatic cancer constitute a heterogeneous group,
and SPC may work better for patients with some pri-
mary diagnoses than for others, and this could weaken
the power of our trial. It is also possible that the various
SPC centres are better at treating different symptoms,
and that a high effect from one SPC centre is weakened
by the others. However, the heterogeneity of patients
and centres increase the generalisability of our results.
When the trial started we had different inclusion criteria
from what has been presented here. Originally, the pa-
tients needed to have two palliative needs instead of only
one, and the definition of palliative need was originally
stricter (in order to have a palliative need the patients had
to consider the symptom to be a problem and have a needfor help with the symptom). However, after the first two
months of the trial, we realised that our initial inclusion
criteria was too strict. Out of the first 168 patients com-
pleting a screening questionnaire, only eight were rando-
mised. Therefore we changed the inclusion criteria in
order to make a larger proportion of patients eligible. It is
the revised and final inclusion criteria which are presented
in this paper. The change was approved by the local re-
gional ethics committee, the funding body and reported
to clinicaltrials.gov.
Conclusion
The DanPaCT trial aims at investigating whether patients
with metastatic cancer who report palliative needs in a
screening will benefit from being referred to ‘early SPC’.
We also study the economical and survival consequences
of such a referral.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ATJ, AD, TBV, JL, PS, CG, MAN, MAP, LEL, LP, PF, IJH, MG took part in
designing the trial. JL, CG, MAP, PF with special competence in RCT and/or
statistical analysis, and ATJ, AD, TBV, PS, MAN, LEL, LP, IJH, MG with special
competence in palliative care. AD, TBV, PS, MAN, LEL, LP, MG are clinical
investigators and in charge of the data collection, and ASS helped collect
data. ATJ was project coordinator and MG received the funding for the
study. ATJ drafted the paper and all authors read, amended and approved
the final manuscript.
Acknowledgements
We wish to thank the following project nurses for collecting the data:
Agnethe Fløe Nielsen and Sine Jürgensen Stamm Mikkelsen, Aarhus
University Hospital; Lone Thorup Røge and Grethe Christensen, Herning
Sygehus; Berit Schmidt Bigum and Kristina Olesen, Vejle Sygehus; Kirsten
Rasmussen, Line Haslund and Merethe Martin, Odense University Hospital;
and Katrine Eldrup, Helena Lindholm, Louise Christoffersen and Lisbeth Grave
Bendixen, Copenhagen University Hospital (Rigshospitalet). Furthermore, we
wish to thank the palliative care teams for participating in the trial. Last, but
not least, we wish to thank the patients for their participation.
Funding
This work was funded by The Danish foundation TrygFonden [journal
number 7-10-0838A] and the Danish Cancer Society [journal number
R16-A695].
Author details
1Department of Palliative Medicine, The Research Unit, Bispebjerg Hospital
20D, Bispebjerg Bakke 23, DK-2400 Copenhagen, NV, Denmark. 2Palliative
Team Fyn, Odense University Hospital, Odense, Denmark. 3Palliative Team
Vejle, Vejle Hospital, Vejle, Denmark. 4Copenhagen Trial Unit, Centre for
Clinical Intervention Research, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark. 5Department of Oncology, Section of
Palliative Medicine, Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark. 6The Palliative Team, Aarhus University Hospital,
Aarhus, Denmark. 7Palliative Team Herning, Herning Hospital, Herning,
Denmark. 8Institute of Applied Health Sciences, University of Aberdeen
Medical School, Foresterhill, Aberdeen, UK. 9Department of Oncology,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
10King’s College London, Cicely Saunders Institute, Department of Palliative
Care, Policy and Rehabilitation, London, UK. 11Institute of Public Health,
University of Copenhagen, Copenhagen, Denmark.
Received: 24 September 2013 Accepted: 15 October 2013
Published: 24 October 2013
Johnsen et al. BMC Palliative Care 2013, 12:37 Page 6 of 6
http://www.biomedcentral.com/1472-684X/12/37References
1. World Health Organization, World Health Organization. National cancer
control programmes: Policies and managerial guidelines. Geneva: WHO; 2002.
http://www.who.int/cancer/publications/nccp2002/en/index.html.
2. Groenvold M, Hansen MB, Rasmussen M: Report from the Danish palliative
database 2011, [Årsrapport for dansk palliativ database 2011]. Copenhagen;
2012. http://dmcgpal.dk/files/dpd_aarsrapport_2011.pdf.
3. Johnsen AT, Petersen MA, Pedersen L, Groenvold M: Symptoms and
problems in a nationally representative sample of advanced cancer
patients. Palliat Med 2009, 23:491–501.
4. Johnsen AT, Petersen MA, Pedersen L, Houmann LJ, Groenvold M: Do
advanced cancer patients in Denmark receive the help they need? A
nationally representative survey of the need related to 12 frequent
symptoms/problems. Psychooncology 2013, 22:1724–1730.
5. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA,
Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ: Early
palliative care for patients with metastatic non-small-cell lung cancer.
N Engl J Med 2010, 363:733–742.
6. Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, Perez-Cruz P,
Heist RS, Temel JS: Depression and survival in metastatic non-small-cell lung
cancer: effects of early palliative care. J Clin Oncol 2012, 30:1310–1315.
7. Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher
ER, Temel JS: Effect of early palliative care on chemotherapy use and
end-of-life care in patients with metastatic non-small-cell lung cancer.
J Clin Oncol 2012, 30:394–400.
8. American Joint Committee on Cancer: AJCC - cancer staging manual. 7th
edition. Chicago: Springer; 2010. http://www.cancerstaging.org/.
9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A,
Flechtner H, Fleishman SB, Dehaes JCJM, Kaasa S, Klee M, Osoba D, Razavi D,
Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The european-
organization-for-research-and-treatment-of-cancer Qlq-C30 - a quality-of-
life instrument for Use in international clinical-trials in oncology.
J Natl Cancer Inst 1993, 85:365–376.
10. Lo C, Burman D, Rodin G, Zimmermann C: Measuring patient satisfaction
in oncology palliative care: psychometric properties of the FAMCARE-
patient scale. Qual Life Res 2009, 18:747–752.
11. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta
Psychiatr Scand 1983, 67:361–370.
12. Herrmann C: International experiences with the hospital anxiety and
depression scale–a review of validation data and clinical results.
J Psychosom Res 1997, 42:17–41.
13. Petersen MA, Groenvold M, Aaronson NK, Chie WC, Conroy T, Costantini A,
Fayers P, Helbostad J, Holzner B, Kaasa S, Singer S, Velikova G, Young T:
Development of computerized adaptive testing (CAT) for the EORTC
QLQ-C30 physical functioning dimension. Qual Life Res 2011, 20:479–490.
14. Petersen MA, Groenvold M, Aaronson NK, Chie WC, Conroy T, Costantini A,
Fayers P, Helbostad J, Holzner B, Kaasa S, Singer S, Velikova G, Young T:
Development of computerised adaptive testing (CAT) for the EORTC
QLQ-C30 dimensions - general approach and initial results for physical
functioning. Eur J Cancer 2010, 46:1352–1358.
15. King MT: The interpretation of scores from the EORTC quality of life
questionnaire QLQ-C30. Qual Life Res 1996, 5:555–567.
16. SAS Institute Inc: SAS/STAT 9.1 user’s guide. Cary, NC: SAS Institute Inc; 2004.
http://support.sas.com/documentation/onlinedoc/stat/chapters91.html.
17. Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S: Quality of
life in advanced cancer patients: the impact of sociodemographic and
medical characteristics. Br J Cancer 2001, 85:1478–1485.
18. Parker PA, Baile WF, de Moor C, Cohen L: Psychosocial and demographic
predictors of quality of life in a large sample of cancer patients.
Psychooncology 2003, 12:183–193.
19. Brumley R, Enguidanos S, Jamison P, Seitz R, Morgenstern N, Saito S,
McIlwane J, Hillary K, Gonzalez J: Increased satisfaction with care and
lower costs: results of a randomized trial of in-home palliative care. J Am
Geriatr Soc 2007, 55:993–1000.
20. Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ: The comprehensive care
team: a controlled trial of outpatient palliative medicine consultation.
Arch Intern Med 2004, 164:83–91.
21. Jordhoy MS, Fayers P, Loge JH, Ahlner-Elmqvist M, Kaasa S: Quality of life in
palliative cancer care: results from a cluster randomized trial. J Clin Oncol
2001, 19:3884–3894.22. Hughes SL, Cummings J, Weaver F, Manheim L, Braun B, Conrad K: A
randomized trial of the cost effectiveness of VA hospital-based home
care for the terminally ill. Health Serv Res 1992, 26:801–817.
23. Hanks GW, Robbins M, Sharp D, Forbes K, Done K, Peters TJ, Morgan H,
Sykes J, Baxter K, Corfe F, Bidgood C: The imPaCT study: a randomised
controlled trial to evaluate a hospital palliative care team. Br J Cancer
2002, 87:733–739.
24. McWhinney IR, Bass MJ, Donner A: Evaluation of a palliative care service:
problems and pitfalls. BMJ 1994, 309:1340–1342.
25. McCorkle R, Benoliel JQ, Donaldson G, Georgiadou F, Moinpour C, Goodell
B: A randomized clinical trial of home nursing care for lung cancer
patients. Cancer 1989, 64:1375–1382.
26. Zimmer JG, Groth-Juncker A, McCusker J: A randomized controlled study
of a home health care team. Am J Public Health 1985, 75:134–141.
27. Kane RL, Wales J, Bernstein L, Leibowitz A, Kaplan S: A randomised
controlled trial of hospice care. Lancet 1984, 1:890–894.
28. Edmonds P, Karlsen S, Khan S, Addington-Hall J: A comparison of the
palliative care needs of patients dying from chronic respiratory diseases
and lung cancer. Palliat Med 2001, 15:287–295.
29. Higginson IJ, Hart S, Burman R, Silber E, Saleem T, Edmonds P: Randomised
controlled trial of a new palliative care service: compliance, recruitment
and completeness of follow-up. BMC Palliat Care 2008, 7:7.
30. Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P,
Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ: Phase II study:
integrated palliative care in newly diagnosed advanced non-small-cell
lung cancer patients. J Clin Oncol 2007, 25:2377–2382.
31. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin
RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions and outcomes:
meta-epidemiological study. BMJ 2008, 336:601–605.
32. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, Als-Nielsen B, Balk
EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood
L, Moher D, Deeks JJ, Sterne JA: Influence of reported study design
characteristics on intervention effect estimates from randomized,
controlled trials. Ann Intern Med 2012, 157:429–438.
doi:10.1186/1472-684X-12-37
Cite this article as: Johnsen et al.: A randomised, multicentre clinical trial
of specialised palliative care plus standard treatment versus standard
treatment alone for cancer patients with palliative care needs: the
Danish palliative care trial (DanPaCT) protocol. BMC Palliative Care
2013 12:37.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
